Please assess the completion status of the following clinical trial:

Trial Title: Long Term Administration of Inhaled Mannitol in Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Have given written informed consent to participate in this study in accordance with local regulations~2. Have a confirmed diagnosis of cystic fibrosis (positive sweat chloride value ≥ 60 mEq/L) and/or genotype with two identifiable mutations consistent with CF, accompanied by one or more clinical features consistent with the CF phenotype)~3. Be aged \> 6 years old~4. Have FEV1 \>40 % and \< 90% predicted~5. Be able to perform all the techniques necessary to measure lung function~Exclusion Criteria:~1. Investigators, site personnel directly affiliated with this study, or their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biologically or legally adopted.~2. Be considered terminally ill or eligible for lung transplantation~3. Have had a lung transplant~4. Be using nebulized hypertonic saline in the 4 weeks prior to visit 1~5. Have had a significant episode of hemoptysis (\>60 mL) in the three months prior to enrolment~6. Have had a myocardial infarction in the three months prior to enrolment~7. Have had a cerebral vascular accident in the three months prior to enrolment~8. Have had major ocular surgery in the three months prior to enrolment~9. Have had major abdominal, chest or brain surgery in the three months prior to enrolment~10. Have a known cerebral, aortic or abdominal aneurysm~11. Be breast feeding or pregnant, or plan to become pregnant while in the study~12. Be using an unreliable form of contraception (female subjects at risk of pregnancy only)~13. Be participating in another investigative drug study, parallel to, or within 4 weeks of visit 0~14. Have a known allergy to mannitol~15. Be using beta blockers~16. Have uncontrolled hypertension - systolic BP \> 190 and / or diastolic BP \> 100~17. Have a condition or be in a situation which in the Investigator's opinion may put the subject at significant risk, may confound results or may interfere significantly with the patient's participation in the study~18. Be 'Mannitol Tolerance Test positive'~    -

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): active treatment
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).